Fact-checked by Grok 2 weeks ago

Polyketide synthase

Polyketide synthases (PKSs) are a family of multifunctional enzymes belonging to the (FAS) superfamily that catalyze the of s, a structurally diverse group of secondary metabolites produced primarily by , fungi, and . These enzymes assemble polyketide chains through iterative decarboxylative Claisen condensations of acyl units, typically derived from or methylmalonyl-CoA, followed by optional reductions, dehydrations, and cyclizations to generate bioactive compounds such as antibiotics (e.g., erythromycin), immunosuppressants, and anticancer agents. Unlike FAS, which produce uniform fatty acids, PKSs exhibit programmable specificity, allowing for the creation of thousands of distinct polyketide scaffolds with pharmaceutical relevance. Structurally, PKSs are large multienzyme complexes ranging from 1 to 10 megadaltons, organized as modular assembly lines where functional domains are fused into polypeptides. Key domains include the ketosynthase (KS) for chain elongation, acyltransferase (AT) for extender unit loading, and acyl carrier protein (ACP) that tethers the growing polyketide chain via a flexible 4'-phosphopantetheine arm. PKSs are classified into types based on architecture: Type I (modular, multidomain proteins like the 6-deoxyerythronolide B synthase, DEBS), Type II (dissociated enzymes for aromatic polyketides), and Type III (standalone chalcone synthase-like enzymes in plants). Within Type I, cis-AT PKSs integrate AT domains within each module, while trans-AT PKSs use separate, diffusible AT enzymes, enabling greater structural diversity. Recent structural studies reveal dimeric, sheet-like organizations stabilized by linker interactions, facilitating efficient chain translocation via mechanisms like the "turnstile" model. The evolutionary origins of PKSs trace back to FAS-like ancestors, with diversification driven by and domain shuffling, resulting in over 8,000 genomically encoded "orphan" PKS gene clusters awaiting functional . This vast biosynthetic potential underscores PKSs' role in microbial chemical and their exploitation in for engineering novel therapeutics through combinatorial .

Overview

Definition and function

Polyketide synthases (PKSs) are a family of multi-enzyme complexes that catalyze the biosynthesis of , a structurally diverse class of secondary metabolites including such as erythromycin, polyenes such as , and aromatic compounds such as tetracyclines. These enzymes assemble polyketide backbones through the sequential incorporation of acyl units, resulting in natural products with a wide range of biological activities, including , anticancer, and immunosuppressive properties. The primary function of PKSs centers on iterative decarboxylative reactions, where thioesters—most commonly —serve as building blocks to form linear β-ketoacyl chains bound to an (ACP). Unlike fully reducing systems, PKSs incorporate optional β-carbon processing steps, such as ketoreduction, , and enoyl reduction, which can be skipped to retain , hydroxyl, or alkene functionalities and generate structural diversity. The core chain elongation reaction is depicted as: \text{R-C(O)-S-ACP} + \text{HOOC-CH}_2\text{-C(O)-S-CoA} \rightarrow \text{R-C(O)-CH}_2\text{-C(O)-S-ACP} + \text{CO}_2 + \text{CoA-SH} This condensation, facilitated by the ketosynthase () domain, decarboxylates the malonyl extender unit to drive carbon-carbon bond formation. PKSs operate through mechanisms highly analogous to those of synthases (), sharing evolutionary origins, precursor pools like , and domain architectures for condensation and processing, but PKSs diverge by allowing programmable incomplete reduction of β-keto intermediates to preserve reactive groups essential for folding and cyclization. This flexibility enables the production of unsaturated or oxygenated scaffolds, contrasting with the saturated generated by . These enzymes are predominantly found in , particularly actinomycetes such as Streptomyces species, as well as in fungi and ; while PKS-like enzymes occur in animals, often as variants producing simpler , recent findings (as of 2024) reveal complex production in certain like molluscs via widespread FAS-like PKS, though such occurrences remain less common than in microbes.

Diversity and occurrence

Polyketide synthases (PKSs) produce a vast array of structurally diverse natural products, ranging from linear chains to complex cyclic and aromatic scaffolds. This diversity arises from variations in chain length, degree of reduction, cyclization patterns, and post-assembly modifications, enabling the biosynthesis of macrolactones such as erythromycin, enediyne antibiotics like , and polyaromatic compounds including . PKSs are widely distributed across prokaryotes and eukaryotes, with bacterial sources predominating in the production of bioactive metabolites. In bacteria, particularly actinomycetes like species, PKSs synthesize numerous antibiotics and antitumor agents. Fungal PKSs, such as those in species, generate cholesterol-lowering compounds like , and often produce hybrid molecules combining polyketide and non-ribosomal peptide moieties through NRPS-PKS fusion enzymes. In plants, type III PKSs, such as chalcone synthase, contribute to phenolic compounds like . Metazoans, including marine sponges, host PKSs primarily through bacterial symbionts that assemble specialized polyketides for . PKS genes are typically organized into biosynthetic gene clusters or operons, which facilitate coordinated expression and of the multi-enzyme . These clusters often include accessory genes for tailoring enzymes, transporters, and regulators, ensuring efficient production of the polyketide scaffold. The evolutionary diversification of PKSs has been driven by , allowing dissemination across microbial taxa and contributing to their broad phylogenetic distribution. Over 10,000 distinct have been identified to date, with many more biosynthetic potentials remaining untapped in underexplored genomes.

Classification

Type I PKS

Type I polyketide synthases (PKSs) are large, multifunctional enzymes organized as megasynthases, consisting of covalently linked polypeptides that assemble complex structures through sequential and modification steps. These systems are characterized by their modular architecture, where each elongation cycle is mediated by a dedicated , distinguishing them from the dissociable enzymes of other PKS types. Type I PKSs can operate in either non-iterative (modular) or iterative modes, with the former using each module once for linear chain extension and the latter reusing modules for repeated cycles. Type I PKSs are subdivided into cis-acyltransferase (cis-AT) and trans-acyltransferase (trans-AT) subtypes based on the organization of the acyltransferase (AT) domain responsible for loading extender units such as or methylmalonyl-CoA. In cis-AT systems, the AT domain is integrated within each module and is typically specific for particular substrates, a configuration common in like actinomycetes. In contrast, trans-AT systems feature a , standalone AT protein that delivers extender units to multiple modules, providing greater substrate flexibility; these are prevalent in and contribute to the diversity of polyketides produced by these organisms. Both subtypes share a core module structure comprising , AT, and (ACP) domains, with optional reductive domains including ketoreductase (KR), dehydratase (DH), and enoylreductase (ER) that control the of the growing chain. A prototypical example of a cis-AT Type I PKS is the 6-deoxyerythronolide B synthase (DEBS) from Saccharopolyspora erythraea, which assembles the 14-membered macrolactone precursor to the antibiotic erythromycin. DEBS consists of three large polypeptides (DEBS1, DEBS2, DEBS3) encoding six modules in total, initiating with a propionyl-CoA starter unit and extending via six methylmalonyl-CoA units, with specific modules incorporating KR, DH, and ER for partial reduction to achieve the desired stereochemistry and functionality. Type I PKSs are further classified by reduction level into fully reducing (FR), partially reducing (PR), and non-reducing (NR) subtypes, where FR and PR systems include active reductive domains to produce aliphatic polyketides, while NR systems lack these domains and instead form aromatic compounds through cyclization. For instance, the iterative NR-PKS 6-methylsalicylic acid synthase (6-MSAS) in fungi like Penicillium patulum synthesizes the simple aromatic polyketide 6-methylsalicylic acid via multiple iterations of malonyl-CoA extension without reduction.

Type II PKS

Type II polyketide synthases (PKSs) are discrete, multidomain enzymes that function iteratively to biosynthesize aromatic polyketides, primarily in bacteria such as Streptomyces species. These systems rely on a minimal set of enzymes, including the ketosynthase α (KSα) for chain elongation, the chain length factor (CLF, also known as KSβ) that controls chain length and facilitates aromatization, and the acyl carrier protein (ACP) that tethers the growing polyketide chain. Accessory enzymes, such as ketoreductases (KR) for β-keto group reduction and aromatase/cyclases (ARO/CYC) for ring folding and aromatization, further modify the intermediate to yield the final aromatic scaffold. Unlike the large, modular assemblies of Type I PKSs, Type II systems use these dissociated components iteratively for efficient production of structurally diverse aromatics. The biosynthetic mechanism of Type II PKSs begins with the loading of a starter unit, typically , onto the ACP, followed by iterative decarboxylative Claisen condensations with units to extend the chain and form a linear poly-β-ketone intermediate. The KSα-CLF heterodimer catalyzes each elongation step, with the CLF ensuring precise chain length by positioning the ACP-bound substrate. Post-elongation, the poly-β-keto chain undergoes programmed folding into specific conformations (e.g., C9-C14 or C7-C12), driven by intrinsic reactivity or accessory enzymes like and , culminating in dehydration, oxidation, and aromatization to produce fused ring systems such as or cores. A classic example is the of actinorhodin, a blue-pigmented benzoisochromanequinone produced by via its minimal PKS (actI-orf1 to orf3), which generates a C16 chain that cyclizes to the aromatic product. Similarly, like , an anticancer agent from , are assembled by a Type II PKS involving iterative condensation to a 21-carbon decaketide, followed by cyclization and post-PKS modifications to form the linear tetracyclic aglycone. These pathways exemplify how Type II PKSs generate bioactive molecules with applications in pigmentation, resistance, and . Type II PKS gene clusters are frequently co-localized with genes encoding tailoring enzymes, such as glycosyltransferases, oxygenases, and methyltransferases, which diversify the scaffold through post-assembly modifications like or . A 2025 review underscores the health impacts of Type II-derived compounds, particularly anticancer anthraquinones like those in , which intercalate DNA and inhibit II, though challenges remain in mitigating . Variations in Type II PKS architecture include hybrid systems in certain , such as those combining Type II and Type III elements to produce extended chains beyond typical aromatic limits, enabling the synthesis of linear or polyene structures.

Type III PKS

Type III synthases (PKSs) represent the simplest class within the PKS family, characterized as compact homodimeric enzymes belonging to the synthase (CHS)-fold superfamily. Unlike types I and II, they lack an (ACP) and instead directly utilize free as the extender unit, paired with starter substrates such as or p-coumaroyl-CoA, to build chains through iterative decarboxylative condensations. These enzymes are predominantly found in and fungi, where they synthesize , but they also occur in , contributing to the structural diversity of secondary metabolites. The biosynthetic mechanism of type III PKSs occurs within a single cavity, employing a conserved cysteine-histidine-asparagine (Cys-His-Asn) to facilitate repeated rounds of , β-keto processing, and cyclization. Typically, these enzymes perform three to four iterative condensations, yielding tetraketide products such as , which undergo spontaneous or enzyme-assisted to form phenolics; longer chains can be produced depending on architecture. A prominent example is chalcone synthase (CHS) in , which condenses one p-coumaroyl-CoA starter with three units to produce naringenin , the foundational scaffold for biosynthesis essential in plant defense and pigmentation. In , enzymes like 1,3,6,8-tetrahydroxynaphthalene synthase (THNS), such as the RppA homolog in species, catalyze the of four units to generate 1,3,6,8-tetrahydroxynaphthalene, a precursor to pigments. Recent studies highlight the functional flexibility of fungal type III PKSs, which produce diverse metabolites including through and minimal clusters often co-localized with tailoring enzymes like cytochrome P450s. These enzymes exhibit variations in operational modes, primarily decarboxylative condensations leading to aromatic products via aldol or Claisen cyclizations for or scaffolds, respectively, though some retain carboxyl groups in intermediates for alternative chain extensions. For instance, fungal enzymes like AiizPKS demonstrate broad acceptance of fatty starters (C9-C10), yielding alkylresorcinols with pharmaceutical potential.

Structure and components

Modules

In modular polyketide synthases (PKSs), primarily those of Type I, modules serve as the organizational units that orchestrate the iterative of polyketide chains. Each is a self-contained functional unit composed of 3 to 7 catalytic domains covalently linked within one or more polypeptides, enabling a processive, where the growing polyketide intermediate remains tethered to the complex without dissociation between elongation cycles. This ensures efficient substrate channeling and structural diversity in the final products, as the sequence and domain composition of modules dictate the chain length, branching, and modifications. The overall organization of a modular PKS typically commences with a loading module, which includes an domain to select and activate a starter unit (such as a propionyl group) and load it onto an domain, often preceded by a domain in some systems. This is followed by a series of elongation modules, each minimally containing a domain for decarboxylative , an AT domain to incorporate extender units like , and an domain to tether the β-ketoacyl intermediate. Additional optional domains within elongation modules—such as ketoreductase (KR), dehydratase (DH), and —perform stereospecific reductions and dehydrations on the β-keto group during each . Intermodular transfer of the elongated chain relies on docking domains located at the of the upstream and of the downstream , which mediate specific, non-covalent recognition to ensure ordered progression along the assembly line.00156-X) A representative example is the pikromycin PKS from , which features one loading module and six elongation modules distributed across four polypeptides (PikAI–PikAIV), directing the of intermediates that cyclize to form 12- or 14-membered macrolactone rings in products like methymycin and pikromycin, respectively. The precise order of these modules determines the carbon chain length and positions of functional groups, highlighting how modularity underpins product specificity. In trans-AT PKS systems, where AT activity is provided by discrete, standalone enzymes rather than integrated domains, specialized intermodular linkers—such as the motif—facilitate the structural organization of modules into a cohesive megacomplex, and certain variants enable module skipping through mechanisms like alternative translation starts, allowing control over chain extension and final product size.

Domains

Polyketide synthases (PKSs) are composed of multiple catalytic and carrier domains that work in concert to assemble polyketide chains. The core domains include the ketosynthase (KS), or malonyl/acetyl transferase (MT), and (ACP). The KS domain catalyzes the decarboxylative to form carbon-carbon bonds during chain elongation, utilizing a conserved residue in its to accept the acyl chain from the ACP. The AT (or MT in fungal systems) domain selects and transfers extender units, such as or methylmalonyl-CoA, to the ACP via a serine nucleophile in a two-step transacylation , determining substrate specificity through sequence motifs in its . The ACP domain serves as the central scaffold, tethering the growing polyketide chain via a 4'-phosphopantetheine (Ppant) arm attached to a serine residue, which enables flexible shuttling of intermediates between other domains over distances up to approximately 18 . Reductive domains modify the β-keto group introduced during each elongation cycle and are optional depending on the desired structure. The ketoreductase () domain reduces the β-ketoacyl-ACP to a β-hydroxyacyl-ACP using NADPH, exerting stereocontrol over both α- and β-carbon centers, as seen in its ability to epimerize α-methyl groups in certain modules. The dehydratase (DH) domain subsequently eliminates water from the β-hydroxyacyl-ACP to form a trans- or cis-α,β-unsaturated , featuring a double-hotdog that accommodates the . The enoylreductase () domain then reduces the α,β-enoyl-ACP to the saturated acyl-ACP using NADPH, influencing the of adjacent methyl groups. Additional domains handle chain release and post-assembly modifications. The thioesterase (TE) domain cleaves the completed polyketide from the ACP through or intramolecular nucleophilic attack, often forming macrocycles, and adopts a dimeric α/β fold with a substrate-binding channel. In non-reducing PKSs (NR-PKSs), (CYC) and aromatase (ARO) domains promote regiospecific cyclization and aromatization of the polyketide chain, with di-domain ARO/ structures revealing N-terminal recognition motifs for chain length specificity. Domain interactions are mediated by dynamic docking and linkages, exemplified by the ACP's Ppant arm forming such as ACP-S-C(O)-R with the intermediate R, which transfers to the KS for . The ACP docks specifically with the KS via its helix II region, positioning the Ppant arm for efficient delivery, as visualized in high-resolution structures. Recent cryo-EM studies (2024) of full-length Type I PKS modules, such as DEBS module 1 and PikAIII, reveal asymmetric megasynthase conformations with two reaction chambers and turnstile-like ACP movements, enabling ordered domain access during . In contexts, domain swapping—such as exchanging AT or KR domains between modules—has been exploited to alter specificity and , producing hybrid while preserving overall assembly-line fidelity. These domains integrate into larger modules to facilitate iterative chain extension, as detailed in the modules section.

Biosynthetic mechanism

Chain initiation and elongation

Chain initiation in polyketide synthases (PKSs) occurs through the loading module, where an acyltransferase (AT) domain selectively transfers a starter unit, such as propionyl-CoA, onto the (ACP) via to form a bond with the ACP's phosphopantetheine arm. This step primes the growing chain, with the ACP tethering the intermediate throughout biosynthesis to facilitate subsequent reactions. In parallel, extender units like are loaded onto a separate ACP domain by another AT, setting the stage for chain extension; of this malonyl unit occurs during the subsequent condensation step rather than independently. Elongation proceeds via the ketosynthase (KS) domain, which catalyzes a decarboxylative between the ACP-tethered growing chain (initially the starter unit) and the malonyl-ACP extender. The mechanism involves nucleophilic attack by the derived from the decarboxylated malonyl unit on the carbonyl of the acyl chain, extending the by two carbons and yielding a β-ketoacyl-ACP . This reaction can be represented as: \text{R-C(O)-S-KS} + \ce{^{-}OOC-CH2-C(O)-S-ACP} \rightarrow \text{R-C(O)-CH2-C(O)-S-ACP} + \ce{CO2} where R represents the growing polyketide chain transferred to the KS active site cysteine prior to condensation. The KS ensures stereospecificity in the condensation geometry, typically favoring the formation of the thermodynamically stable β-keto product without introducing new chiral centers at this stage. These initiation and elongation steps repeat iteratively, with the chain remaining covalently bound to the ACP for 4–20 cycles depending on the PKS system, adding successive two-carbon units to build the polyketide backbone. In Type I PKSs, each cycle occurs within dedicated modules, with inter-module transfer of the ACP-bound facilitated by domains that ensure processive . By contrast, Type II and Type III PKSs employ iterative reuse of minimal domain sets (KS, AT, ACP in Type II; standalone active sites in Type III) for multiple rounds of elongation without modular segmentation.

Modification and termination

In polyketide biosynthesis, post-condensation modifications diversify the growing chain by altering functional groups introduced during elongation. Ketoreductase () domains stereospecifically reduce β-ketoacyl intermediates to β-hydroxyacyl groups, while dehydratase (DH) domains eliminate water to form α,β-unsaturated enoyl groups, and enoylreductase (ER) domains further saturate these to alkyl chains, with the presence or absence of these optional domains determining the of the final product. Methyltransferase (MT) domains incorporate methyl groups using S-adenosylmethionine (), often at C- or O-positions to enhance structural complexity, as seen in certain aromatic polyketides. Cyclization mechanisms finalize the polyketide core by forming rings through intramolecular reactions. In non-reducing polyketide synthases (NR-PKS), product template (PT) domains guide first-ring cyclization via aldol or Claisen condensations, where the —such as C2-C7 versus C2-C11—determines the scaffold, exemplified by C2-C7 aldol cyclization yielding resorcylic acid like radicicol. Dieckmann condensations, facilitated by reductase-like domains in some NR-PKS, enable formation by intramolecular attack on the , producing tetramate or rings in compounds like equisetin. follows in many cases, driven by aromatase/cyclase (ARO/CYC) domains in type II PKS, which dehydrate and oxidize polyene intermediates to form rings, as in the C7-C12 cyclization of actinorhodin. Termination releases the mature polyketide from the synthase. Thioesterase (TE) domains typically hydrolyze the bond for linear products or catalyze macrolactonization by nucleophilic attack of a hydroxyl on the thioester carbonyl, as in the pikromycin pathway where TE promotes 14-membered ring closure. In hybrid PKS-NRPS systems, TE off-loads the polyketide chain to a non-ribosomal synthetase (NRPS) module for further peptide extension and cyclization. Type III PKS exhibit auto-termination after 3-4 elongation cycles via spontaneous hydrolysis or intrinsic cyclization, releasing triketide or tetraketide products like acylphloroglucinols without dedicated TE domains. Recent studies on thioesterase evolution highlight opportunities for engineering selectivity. Directed evolution of a modular PKS TE from the pikromycin pathway identified mutations enhancing macrolactonization of hybrid amide-containing intermediates, achieving a six-fold yield increase for unnatural macrocyclic ring systems and revealing key residues influencing substrate specificity.

Biological roles

Pharmacological relevance

Polyketides biosynthesized by polyketide synthases (PKS) represent a cornerstone of modern pharmacology, with numerous compounds serving as the basis for FDA-approved therapeutics across multiple disease areas. These natural products and their derivatives exhibit diverse mechanisms of action, targeting bacterial protein synthesis, fungal membranes, DNA replication, and cellular signaling pathways, among others. Their structural complexity and potent bioactivity have made them indispensable in treating infections, cancers, and metabolic disorders, though production challenges persist. In the realm of antibiotics, PKS-derived polyketides have been pivotal in combating bacterial infections. Macrolides such as erythromycin, produced by type I PKS in Saccharopolyspora erythraea, bind to the 50S subunit of the bacterial ribosome, inhibiting translocation during protein synthesis and exhibiting activity against Gram-positive bacteria. Tetracyclines, synthesized via type II PKS in Streptomyces species, reversibly bind to the 30S ribosomal subunit, blocking tRNA attachment and halting protein synthesis in a broad spectrum of bacteria, including those causing acne and respiratory infections. However, rising antibiotic resistance has prompted semi-synthetic modifications; for instance, clarithromycin, derived from erythromycin through methylation, enhances acid stability and tissue penetration while retaining the ribosomal binding mechanism. Anticancer applications of PKS polyketides leverage their ability to disrupt DNA and cellular architecture. Anthracyclines like doxorubicin, generated by type II PKS in Streptomyces peucetius, intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cancer cells; it is widely used in treating leukemias, lymphomas, and solid tumors. Enediynes, such as calicheamicin produced by Micromonospora echinospora, feature a potent DNA-cleaving warhead activated by thiol reduction, and in clinical use, calicheamicin γ1 is conjugated to antibodies (e.g., in gemtuzumab ozogamicin) for targeted delivery to CD33-positive acute myeloid leukemia cells. Beyond antimicrobials and cytotoxics, PKS polyketides address and metabolic conditions. (rapamycin), a type I PKS product from , forms a complex with FKBP12 that allosterically inhibits , suppressing T-cell proliferation and production; it is approved for preventing organ transplant rejection and treating . Statins like , biosynthesized by type I PKS in , competitively inhibit , the rate-limiting enzyme in biosynthesis, reducing cardiovascular risk through lowered LDL levels. Epothilones, such as ixabepilone (a semi-synthetic of epothilone B from Sorangium cellulosum type I PKS), stabilize by binding β-tubulin, preventing depolymerization and inducing mitotic arrest; it is indicated for resistant to taxanes. Over 20 FDA-approved drugs derive from PKS polyketides, underscoring their clinical impact, yet challenges in commercialization remain. Native microbial producers often yield low titers due to complex regulatory networks and slow growth, necessitating optimization or . Total is rare owing to the intricate and macrocyclic architectures, favoring semi-synthesis or biosynthetic for analogs.

Ecological significance

Polyketides serve critical functions in microbial defense within natural ecosystems, particularly by enabling to outcompete rivals. Soil-dwelling streptomycetes, such as species, produce polyketide-based antibiotics like and erythromycin to inhibit the growth of neighboring and fungi, thereby securing nutrient resources in nutrient-limited environments. Similarly, the polyketide antifungal , synthesized by , targets in fungal membranes, providing a competitive edge against fungal antagonists in soil microbiomes. In addition to defense, polyketides facilitate intercellular signaling and predator deterrence. The blue pigment actinorhodin, produced by coelicolor, acts as a quorum-sensing signal that coordinates production and community behaviors in response to environmental cues like iron scarcity, enhancing group-level survival in soil biofilms. Fungal polyketides such as , emitted by , function as toxins that deter predators and suppress competing microbes, promoting fungal dominance in fruit and soil niches. Polyketides also underpin symbiotic interactions across ecosystems. In lichens, fungal mycobionts produce polyketides like depsides and depsidones via type I PKS, which protect the algal photobiont from stresses and stabilize the mutualistic partnership. sponge-associated synthesize polyketides through dedicated PKS pathways, contributing to host defense against pathogens and facilitating nutrient exchange in the . In , type III PKS-derived , such as those in floral nectaries, attract pollinators by providing visual and olfactory cues, supporting reproductive success and . A 2023 study revealed that fungal , including production, is regulated by an complex (CsdA/RsdA), which fine-tunes to adapt to ecological pressures like availability. Many biosynthetic gene clusters remain silent under standard conditions but activate in response to environmental stresses, such as oxidative damage or limitation, allowing microbes to produce defensive compounds on demand. Overall, polyketides enhance soil diversity by modulating microbial interactions and , while undiscovered pathways in marine actinomycetes suggest untapped ecological roles in oceanic carbon cycling and symbioses.

Engineering and future directions

Synthetic biology approaches

Synthetic biology approaches to polyketide synthase (PKS) engineering leverage the modular architecture of these enzymes to generate novel polyketides with altered structures and properties. By manipulating specific domains or entire modules, researchers can redirect incorporation and chain modification, enabling the production of compounds not found in . These strategies often involve techniques to create hybrid enzymes, which are then expressed in suitable host organisms for scalable . Domain and module engineering represent foundational methods for tailoring PKS activity. Swapping acyltransferase (AT) domains alters substrate specificity, allowing incorporation of non-native extender units such as methylmalonyl-CoA instead of , as demonstrated in engineered DEBS modules that produced branched-chain s. Similarly, deletion or inactivation of reductive domains, such as ketoreductases () and dehydratases (DH), prevents β-carbon reduction, yielding unreduced polyketide analogs with preserved keto groups, exemplified by modifications to the PKS that generated fully unsaturated products. Heterologous expression systems facilitate the testing and optimization of engineered PKS constructs outside their native hosts. Escherichia coli and Saccharomyces cerevisiae are commonly used due to their genetic tractability and established metabolic engineering tools, though challenges like improper protein folding and assembly of large multidomain PKSs persist in these prokaryotic and eukaryotic systems, respectively. A prominent example is the expression of the 6-deoxyerythronolide B synthase (DEBS) in engineered E. coli strains, which produces the erythromycin precursor 6-dEB at titers exceeding 1 g/L after pathway optimization, including co-expression of propionyl-CoA carboxylase for precursor supply. Combinatorial biosynthesis expands structural diversity by mixing modules from disparate PKS pathways, creating hybrid capable of novel chain elongations. For instance, swapping modules between the erythromycin (DEBS) and PKSs has yielded with modified structures, enhancing potency against resistant bacterial strains. This approach exploits inter-module interfaces to maintain catalytic fidelity, though compatibility issues can reduce yields. Recent innovations include gene conversion techniques for iterative PKS editing, inspired by natural evolutionary mechanisms, enabling successive domain replacements without disrupting overall synthase integrity. A 2025 study demonstrated this method's application to modular PKSs, achieving up to threefold improvements in analog production through targeted homology-directed repairs. Additionally, fusions between non-ribosomal peptide synthetases (NRPS) and PKS modules generate hybrid -peptide molecules, as seen in engineered NRPS-PKS chimeras that incorporate into polyketide backbones for enhanced bioactivity. CRISPR-based tools have accelerated PKS engineering by enabling precise cluster activation and modification. CRISPR-Cas9 knock-in strategies activate silent biosynthetic gene clusters (BGCs) in streptomycetes by inserting strong promoters upstream of PKS genes, boosting titers of like erythromycin by up to 6-fold. These methods address regulatory barriers but require careful design to avoid off-target effects in complex actinomycete genomes.

Recent advances

Recent advances in have significantly enhanced understanding of polyketide synthase (PKS) architecture, particularly through the integration of cryo-electron microscopy (cryo-EM) and predictions for full-length Type I modular PKS models. In 2024, high-resolution cryo-EM structures of enzymes like Lsd14 and DEBS module 1 revealed asymmetric domain arrangements and flexible linkers that facilitate substrate channeling and conformational dynamics during biosynthesis. Similarly, -guided confirmed docking mechanisms between (ACP) domains and downstream ketosynthases, highlighting the role of flexible inter-domain linkers in modular assembly-line efficiency. Computational tools have accelerated PKS engineering by enabling retrobiosynthetic design of chimeric systems. The BioPKS pipeline, introduced in 2025, automates the integration of multifunctional Type I PKS modules with monofunctional enzymes to predict and construct novel pathways, demonstrating successful targeting of complex carbon backbones. Complementing this, strategies targeting thioesterase (TE) domains have improved product yields in modular PKS by optimizing release mechanisms, as shown in high-throughput assessments of pentaketide synthases. New metabolite discoveries underscore the biosynthetic versatility of PKS enzymes. In 2025, studies revealed functional flexibility in Type III PKS, enabling iterative elongation to produce diverse structures beyond canonical , including those with ecological roles in microbial interactions. Concurrently, genomic analysis linked a PKS (pks1) in atroviride to the of 6-pentyl-α-pyrone, a with properties, confirming its essential role via experiments. Engineering breakthroughs have expanded PKS applications toward sustainable chemicals. In 2024, repurposing a fully reducing PKS module from a bacterial achieved de novo production of 2-methyl Guerbet-like , precursors for biofuels, with titers exceeding 100 mg/L in engineered . Regulatory insights from fungal systems further advanced control mechanisms; a 2023 study identified an RNA-binding protein complex (CsdA/RsdA) that governs by modulating PKS in , offering targets for enhanced metabolite yields. A 2025 review on Type II PKS emphasized their health impacts, detailing how aromatic polyketides like contribute to anticancer therapies while addressing gaps in engineering novel substrates from marine-derived clusters for broader therapeutic applications.

References

  1. [1]
    Structure and Mechanisms of Assembly-Line Polyketide Synthases
    Aug 1, 2025 · Here, we review our current understanding of ... Structure–function analysis of the extended conformation of a polyketide synthase module.
  2. [2]
    The structure of a polyketide synthase bimodule core - PMC
    Sep 21, 2022 · Polyketide synthases (PKSs) are biosynthetic factories, primarily occurring in microbes, for the production of bioactive secondary metabolites, ...
  3. [3]
    Polyketide - an overview | ScienceDirect Topics
    Polyketides (PKs) represent a group of highly diverse secondary metabolites which comprises enediynes, macrolides, polyenes, polyethers, and polyphenols ( ...
  4. [4]
    Structure and Mechanism of Assembly Line Polyketide Synthases
    Assembly line polyketide synthases (PKSs) are remarkable multifunctional catalytic machines responsible for the biosynthesis of a structurally diverse range of ...Missing: definition | Show results with:definition
  5. [5]
    Polyketide Synthase - an overview | ScienceDirect Topics
    Polyketide synthase (PKS) is defined as a multi-enzymatic complex that synthesizes polyketide compounds using acyl-coenzyme A as a substrate, elongated by ...
  6. [6]
    Biosynthesis of Polyketide Synthase Extender Units - PMC
    The KS domain catalyzes the decarboxylative Claisen condensation between a neighboring ACP-linked malonate derivative and an ACP-linked acyl thioester to extend ...Missing: equation | Show results with:equation
  7. [7]
    Evolution and Diversity of Assembly-Line Polyketide Synthases
    Dec 15, 2019 · In this review, we provide an overview of previous studies that investigated PKS evolution and propose a model that challenges the currently prevailing view.
  8. [8]
    Polyketide - an overview | ScienceDirect Topics
    PKSs are common within microorganisms like bacteria and fungi, as well as in higher eukaryotes such as plants (Fischbach and Walsh, 2006; Hertweck, 2009).
  9. [9]
    Polyketide Synthase - an overview | ScienceDirect Topics
    Polyketide Synthase is defined as enzymes that catalyze sequential condensations of acyl-CoA thioesters to produce diverse polyketide scaffolds with ...
  10. [10]
    Structural Analysis of Protein-Protein Interactions in Type I ...
    Many polyketide natural products have become important drug molecules, including human antibiotics erythromycin A and tetracycline; veterinary antibiotic ...
  11. [11]
    Biosynthesis of Polyketides in Streptomyces - PMC - NIH
    Some examples of aromatic polyketide produced by Streptomyces are actinorhodin (benzoisochromanequinones), doxorubicin (anthracyclines), jadomycin B ...
  12. [12]
    Diversity of polyketide synthases found in the Aspergillus ... - PubMed
    Mar 14, 2008 · This brief review will discuss the current knowledge in polyketides produced by the various different classes of polyketide synthases (PKSs) ...Missing: plants orchids sponges
  13. [13]
    Surveys of Non-Ribosomal Peptide and Polyketide Assembly Lines ...
    Both bacteria and fungi have numerous hybrid NRPS-PKS pathways. Both fungal and bacterial pathways are often clustered together on the genome, but fungal ...
  14. [14]
    Evolutionary Histories of Type III Polyketide Synthases in Fungi
    Jan 20, 2020 · Type III polyketide synthases (PKSs) produce secondary metabolites with diverse biological activities, including antimicrobials.
  15. [15]
    Widespread Occurrence and Genomic Context of Unusually ... - NIH
    Unexpectedly, the sponge metagenomes were dominated by a ubiquitously present, evolutionarily distinct, and highly sponge-specific group of polyketide synthases ...Missing: fungi Aspergillus orchids
  16. [16]
    Organization of the biosynthetic gene cluster for the polyketide ...
    Chain initiation on the avermectin PKS may require initial acyltransferase and acyl carrier protein domains to load the starting acyl group onto the PKS. Such ...
  17. [17]
    A Polyketide Synthetase Gene Cluster Is Responsible for ...
    Jan 13, 2023 · PKS genes for polyketide biosynthesis are usually organized in one operon in bacteria. The gene clusters encode different metabolic steps ...
  18. [18]
    Evolution of polyketide synthases in bacteria - PMC - NIH
    Thus it appears that bacterial evolution and polyketide evolution are independent of each other, and that horizontal gene transfer is a driver of aromatic ...
  19. [19]
    Horizontal gene transfer and gene conversion drive evolution of ...
    Seventeen modular polyketide synthase clusters were identified that fell into six classes. Gene conversion within clusters was very common.
  20. [20]
    Mapping the biosynthetic pathway of a hybrid polyketide ... - Nature
    Aug 13, 2021 · Polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS) hybrid systems typically use complex protein-protein interactions to ...
  21. [21]
    Diversification of polyketide structures via synthase engineering - PMC
    As briefly mentioned in the Introduction section, modular type I PKSs are categorized into cis-AT and trans-AT systems. In cis-AT systems, such as DEBS and ...
  22. [22]
    None
    ### Summary of Type I PKS Structure and Details from the Document
  23. [23]
    Phylogenomic analysis of type I polyketide synthase genes ... - PNAS
    Other Fungal and Bacterial PKSs. The third main fungal PKS clade comprised the 6-methylsalicylic acid-type (i.e., simple aromatic) of PKSs that make 6 ...
  24. [24]
    Type II Polyketide Synthases: impact on human health, current ...
    Sep 22, 2025 · Type I PKS and FAS are large polypeptide chains that consist of multiple domains linked covalently together that can further be divided into ...
  25. [25]
    Strategic Acyl Carrier Protein Engineering Enables Functional Type ...
    Jan 2, 2025 · Aromatic polyketides are produced by type II polyketide synthase (PKS) systems, each minimally composed of a ketosynthase-chain length factor ( ...
  26. [26]
    Structural and functional analysis of two di-domain aromatase ...
    The type II polyketide synthase (PKS) is composed of dissociated enzymes that are used iteratively and are responsible for the elongation, cyclization, and ...<|control11|><|separator|>
  27. [27]
    New insights into bacterial type II polyketide biosynthesis.
    Feb 21, 2017 · ... type II polyketide synthase (PKS) pathway in aurachin biosynthesis ... ACP, acyl carrier protein; KS, ketosynthase. Download as a ...
  28. [28]
    Structural basis for selectivity in a highly reducing type II polyketide ...
    May 4, 2020 · ... (ACP=KS-CLF) tripartite complex. The latter structure revealed ... type II polyketide synthase that catalyzes polyene formation. Angew ...
  29. [29]
    Biosynthesis of aromatic polyketides in microorganisms using type II ...
    May 24, 2020 · Type II PKSs are mainly responsible for producing aromatic polyketides by catalyzing iterative Claisen condensation reaction usually using ...
  30. [30]
    Isolation, Characterization, and Heterologous Expression of the ...
    Biosynthesis of anthracyclines begins with the condensation of small carboxylic acids by the iterative action of a type II PKS composed of two ketosynthases (KS ...
  31. [31]
    The chalcone synthase superfamily of type III polyketide synthases
    Dec 13, 2002 · This review covers the functionally diverse type III polyketide synthase (PKS) superfamily of plant and bacterial biosynthetic enzymes, from the ...Missing: fold | Show results with:fold
  32. [32]
    Exploiting the Biosynthetic Potential of Type III Polyketide Synthases
    This review summarizes the insights gained from research on type III PKSs, from the discovery of chalcone synthase in plants to novel PKSs in bacteria and ...
  33. [33]
    Chalcone synthase and its functions in plant resistance - PMC
    Chalcone synthase (CHS, EC 2.3.1.74) is a key enzyme of the flavonoid/isoflavonoid biosynthesis pathway. Besides being part of the plant developmental program ...
  34. [34]
    Unravelling the Functional Diversity of Type III Polyketide Synthases ...
    Sep 4, 2025 · Type III polyketide synthases (T3PKSs) are enzymes that produce diverse compounds of ecological and clinical importance. While well-studied ...
  35. [35]
    Structure of a modular polyketide synthase - PMC - PubMed Central
    Type I modular polyketide synthases (PKSs) are enzyme assembly lines for the synthesis of chemically diverse polyketide natural products that form the basis ...Missing: definition | Show results with:definition
  36. [36]
    Interrogating the Molecular Basis for Multiple Macrolactone Ring ...
    The pikromycin PKS is comprised of a single loading module (LM) and six elongation modules that span four polypeptide chains (PikAI-PikAIV). Interpolypeptide ...
  37. [37]
    Assessing and harnessing updated polyketide synthase modules ...
    Aug 1, 2024 · In this study, we sought to test the limits of PKS engineering with updated modules and identify impediments to programming synthases that ...
  38. [38]
    The LINKS motif zippers trans-acyltransferase polyketide synthase ...
    In this work we analyze ten crystal structures of trans-acyltransferase polyketide synthases ketosynthase domains, seven of which are reported here for the ...Missing: intermodular linkers
  39. [39]
    Structural and functional analysis of two di-domain aromatase ...
    Enzymes known as aromatase/cyclases (ARO/CYCs) catalyze regiospecific cyclization and aromatization during type II polyketide biosynthesis. Understanding how ...
  40. [40]
    Architecture of Full-length Type I Modular Polyketide Synthases ...
    Type I modular polyketide synthases construct polyketide natural products in an assembly line-like fashion, where the growing polyketide chain attached to ...
  41. [41]
    Engineering strategies for rational polyketide synthase design
    Jun 25, 2018 · In this review, we focus on a multitude of approaches to engineer modular PKSs by swapping and replacing PKS modules and domains.
  42. [42]
    Biosynthetic Cyclization Catalysts for the Assembly of Peptide and ...
    May 7, 2021 · The studies summarized here highlight the remarkable diversity of NRPS and PKS cyclization catalysts for the production of biologically ...
  43. [43]
    Rational reprogramming of fungal polyketide first-ring cyclization
    Resorcylic acid lactones and dihydroxyphenylacetic acid lactones represent important pharmacophores with heat shock response and immune system modulatory ...Abstract · Results And Discussion · Portability Of Aldol...
  44. [44]
    Exploiting the Biosynthetic Potential of Type III Polyketide Synthases
    This review summarizes the insights gained from research on type III PKSs, from the discovery of chalcone synthase in plants to novel PKSs in bacteria and fungi ...Missing: definition paper
  45. [45]
  46. [46]
    Actinomycete-Derived Polyketides as a Source of Antibiotics and ...
    Since then, several valuable polyketide drugs, such as erythromycin A, tylosin, monensin A, rifamycin, tetracyclines, amphotericin B, and many others were ...
  47. [47]
    Spirotetronate Polyketides as Leads in Drug Discovery
    Dec 1, 2014 · The search for new antitumor antibiotics led to the discovery of chlorothricin (1), a complex polyketide produced by various Streptomyces ...Missing: immunosuppressants | Show results with:immunosuppressants
  48. [48]
    Insights into polyketide biosynthesis gained from repurposing ...
    Jun 1, 2016 · Insights into polyketide biosynthesis gained from repurposing antibiotic-producing polyketide synthases to produce fuels and chemicals.
  49. [49]
    Biotechnology of polyketides: New breath of life for the novel ... - NIH
    Examples of natural products derived from these multicatalytic enzymes include the macrolides (erythromycin) and polyenes (nystatin). The type II PKSs (i.e., ...
  50. [50]
    Epothilones as Natural Compounds for Novel Anticancer Drugs ...
    Epothilone have mechanisms of action similar to paclitaxel by inducing tubulin polymerization and apoptosis with low susceptibility to tumor resistance ...Missing: immunosuppressants | Show results with:immunosuppressants
  51. [51]
    Challenges of functional expression of complex polyketide ...
    However, industrial fermentation often suffers from the low production yield and poor growth characteristics of the polyketide-producing microbes [6].
  52. [52]
    Challenges and discoveries in the total synthesis of complex ...
    Oct 25, 2017 · We provide an overview of recent research endeavors that have culminated in the total synthesis of several challenging polyketide natural products with ...
  53. [53]
    Natural product discovery in soil actinomycetes: unlocking their ...
    For example, many Streptomyces contain a BGC encoding a polyketide spore pigment, which gives them their strain-specific spore colours 25, 26. The widespread ...Review · Ecology Of Nps In Soil... · References And Recommended...
  54. [54]
    Streptomyces polyketides mediate bacteria–fungi interactions ...
    Jun 15, 2023 · Here we show that arginine-derived polyketides (arginoketides) produced by Streptomyces species mediate cross-kingdom microbial interactions with fungi.
  55. [55]
    Iron competition triggers antibiotic biosynthesis in Streptomyces ...
    Jan 28, 2020 · ... quorum sensing, and physical interaction) and abiotic stresses ... actinorhodin biosynthesis and its ecological role. Our findings ...
  56. [56]
    Patulin Degradation by the Biocontrol Yeast Sporobolomyces sp. Is ...
    Feb 10, 2017 · The ecological role of PAT has not been fully elucidated, and it is likely to help in competition against other microbes that PAT-producing ...
  57. [57]
    How to build a lichen: from metabolite release to symbiotic interplay
    Jan 29, 2023 · Therefore, polyketides produced by lichen mycobionts help sustaining the symbiosis by protection from biotic stress factors, and may also ...
  58. [58]
    Polyketide Synthases in the Microbiome of the Marine Sponge ...
    While symbiotic bacteria are commonly recognized as the main producers of the polyketides found in sponges, our results suggest that bacteria are not ...
  59. [59]
    Engineering a Plant Polyketide Synthase for the Biosynthesis ... - NIH
    In nature, flavonoids are important for plant growth and reproduction, for attracting pollinators, and for protecting against biotic and abiotic stresses ...Missing: symbiosis lichen sponge
  60. [60]
    Fungal secondary metabolism is governed by an RNA-binding ... - NIH
    Nov 14, 2023 · Here, we discover that interaction of an RNA-binding protein CsdA with a regulator RsdA coordinates fungal secondary metabolism.
  61. [61]
    Activation of a Silent Fungal Polyketide Biosynthesis Pathway ...
    Through transcriptome analysis we found that another silent secondary metabolite gene cluster located on chromosome VIII coding for asperfuranone biosynthesis ...
  62. [62]
    Marine Actinomycetes, New Sources of Biotechnological Products
    Many marine actinomycetes demonstrate anti-biofouling properties. In a study of 40 marine actinomycetes isolated from a soil sample of Rhizophora apiculata, ...1. Introduction · 2. Medical Applications · 5. Areas Of Further...
  63. [63]
    Mutagenesis supports AlphaFold prediction of how modular ...
    Mutagenesis supports AlphaFold prediction of how modular polyketide synthase acyl carrier proteins dock with downstream ketosynthases · Melissa Hirsch · Ronak R ...
  64. [64]
    Merging the computational design of chimeric type I polyketide ...
    Jul 1, 2025 · We introduce BioPKS pipeline, an automated retrobiosynthesis tool combining multifunctional type I polyketide synthases (PKSs) and monofunctional enzymes.
  65. [65]
    Functional flexibility of a type III polyketide synthase in ... - Cell Press
    T3PKSs in recent times have displayed immense biosynthetic versatility to generate functionally crucial metabolites with diverse molecular structures.
  66. [66]
    Linking a polyketide synthase gene cluster to 6-pentyl-alpha-pyrone ...
    Apr 21, 2025 · Environmental factors such as light, temperature, and pH modulate SM production in fungi [22]. Accordingly, 6-PP biosynthesis in T. atroviride ...
  67. [67]
    Repurposing a Fully Reducing Polyketide Synthase toward 2-Methyl ...
    We highlight recent advances, such as de novo design and directed evolution, and discuss parameters that make a good reproducible biocatalytic process for ...
  68. [68]
    Fungal secondary metabolism is governed by an RNA-binding ...
    Nov 14, 2023 · Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. ... Microbial melanin: recent advances in ...